R44TR005293
Project Grant
Overview
Grant Description
Novel immunotherapy against MOG antibody disease - Project summary/abstract
Myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOGAD) is a rare disease characterized as a neurological, inflammatory, demyelinating disorder of the central nervous system.
The symptoms of MOGAD include vision loss, symptoms associated with damage to the spinal cord, as well as seizures.
While the current standard of care against MOGAD includes steroids and immunosuppressants, they are associated with systemic immunosuppression with complications and frequent debilitating relapses.
Thus, there is an urgent need for new targeted treatment options for MOGAD patients.
As MOG is the sole target antigen in MOGAD patients, MOG is an attractive target.
Here, we propose to develop a novel nanoparticle platform for the treatment of MOGAD.
Toward this goal, we have developed synthetic high-density lipoprotein nanodiscs for efficient delivery of antigen peptides to lymph nodes.
Our preliminary data shows that nanodiscs induce robust antigen-specific immune tolerance and disease modification in murine models of experimental autoimmune encephalomyelitis (EAE) and another autoimmune disorder, type 1 diabetes (T1D).
Based on our compelling proof-of-concept data, here we propose to further develop nanodiscs for the treatment of MOGAD.
Myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOGAD) is a rare disease characterized as a neurological, inflammatory, demyelinating disorder of the central nervous system.
The symptoms of MOGAD include vision loss, symptoms associated with damage to the spinal cord, as well as seizures.
While the current standard of care against MOGAD includes steroids and immunosuppressants, they are associated with systemic immunosuppression with complications and frequent debilitating relapses.
Thus, there is an urgent need for new targeted treatment options for MOGAD patients.
As MOG is the sole target antigen in MOGAD patients, MOG is an attractive target.
Here, we propose to develop a novel nanoparticle platform for the treatment of MOGAD.
Toward this goal, we have developed synthetic high-density lipoprotein nanodiscs for efficient delivery of antigen peptides to lymph nodes.
Our preliminary data shows that nanodiscs induce robust antigen-specific immune tolerance and disease modification in murine models of experimental autoimmune encephalomyelitis (EAE) and another autoimmune disorder, type 1 diabetes (T1D).
Based on our compelling proof-of-concept data, here we propose to further develop nanodiscs for the treatment of MOGAD.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Illinois
United States
Geographic Scope
State-Wide
Evoq Therapeutics was awarded
Project Grant R44TR005293
worth $1,000,000
from National Center for Advancing Translational Sciences in July 2022 with work to be completed primarily in Illinois United States.
The grant
has a duration of 4 years and
was awarded through assistance program 93.350 National Center for Advancing Translational Sciences.
The Project Grant was awarded through grant opportunity PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 7/19/24
Period of Performance
7/15/22
Start Date
6/30/26
End Date
Funding Split
$1.0M
Federal Obligation
$0.0
Non-Federal Obligation
$1.0M
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
R44TR005293
SAI Number
R44TR005293-3461549409
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Small Business
Awarding Office
75NR00 NIH NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
Funding Office
75NR00 NIH NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
Awardee UEI
KC7MPKPPJDE7
Awardee CAGE
7RBJ5
Performance District
IL-90
Senators
Richard Durbin
Tammy Duckworth
Tammy Duckworth
Modified: 7/19/24